Hormone therapy in adults: Suggested revisions to the sixth version of the standards of care

International Journal of Transgenderism

Volumn 11, Issue 3, 2009, Pages 146-182

  Feldman, Jamie ^a   Safer, Joshua ^b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adults; Gender identity disorder; Hormone therapy

Indexed keywords

EID: 73449100807     PISSN: 15532739     EISSN: 14344599     Source Type: Journal    
DOI: 10.1080/15532730903383757     Document Type: Article

References (232)

1. Abbott, D. H., Barnett, D. K., Bruns, C. M., & Dumesic, D. A. (2005).Androgen excess fetal programming of female reproduction: A developmental aetiology for polycystic ovary syndrome? Human Reproduction Update, 11, 357-374.
2. American Academy of Family Physicians. (2005). Definition of family medicine. Retrieved August 10, 2009, from http://www.aafp.org/online/en/home/ policy/policies/f/ fammeddef.html
3. American Diabetes Association. (2007). Standards of medical care in diabetes-2007. Diabetes Care, 30, s4-s41.
4. Amin, S., Zhang, Y., Sawin, C. T., Evans, S. R., Hannan, M. T., Kiel, D. P., et al. (2000). Association of hypogonadism and estradiol levels with bone mineral density in elderly men from the Framingham study. Annals of Internal Medicine, 133, 951-963
5. Asscheman, H., & Gooren, L. J. (1992). Hormone treatment in transsexuals. Journal of Psychology & Human Sexuality, 5(4), 39-54.
6. Asscheman, H., Gooren, L. J., Assies, J., Smits, J. P., & de Slegte, R. (1988). Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals. Clinical Endocrinology, 28, 583-588.
7. Asscheman, H., Gooren, L. J., Megens, J. A., Nauta, J., Kloosterboer, H. J., & Eikelboom, F. (1994). Serum testosterone level is the major determinant of the malefemale differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. Metabolism: Clinical and Experimental, 43, 935-939.
8. Baba, T., Endo, T., Honnma, H., Kitajima, Y., Hayashi, T., Ikeda, H., et al. (2007). Association between polycystic ovary syndrome and female-to-male transsexuality. Human Reproduction (Oxford, England), 22, 1011-1016.
9. Balen, A. (2001). Polycystic ovary syndrome and cancer. Human Reproduction Update, 7, 522-525.
10. Balen, A. H., Schachter, M. E., Montgomery, D., Reid, R. W., & Jacobs, H. S. (1993). Polycystic ovaries are a common finding in untreated female to male transsexuals. Clinical Endocrinology, 38, 325-329.
11. Basson, R., & Prior, J. C. (1998). Hormonal therapy of gender dysphoria: The male-to-female transsexual. In D. Denny (Ed.), Current concepts in transgender identity (pp. 277-296). New York: Garland Publishing.
12. Basson, R., & Pryor, J. (2001). Towards optimal hormonal treatment of male to female gender identity disorder. Journal of Sexual and ReproductiveMedicine, 1(1), 45-51.
13. Bell, J. I., Bishop, M. C., & Britton, B. J. (1977). Haemoperitoneum in a transsexual [Letter to the editor]. Lancet, 2(8042), 817.
14. Berra, M., Armillotta, F., D'Emidio, L., Costantino, A., Martorana, G., Pelusi, G., et al. (2006). Testosterone decreases adiponectin levels in female to male transsexuals. Asian Journal of Andrology, 8, 725-729.
15. Bettocchi, C., Palumbo, F., Cormio, L., Ditonno, P., Battaglia, M., & Selvaggi, F. (2004). The effects of androgen depletion on human erectile function:Aprospective study in male-to-female transsexuals. International Journal of Impotence Research, 16, 544-546.
16. Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., et al. (2006). Testosterone therapy in adult men with androgen deficiency syndromes: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 91, 1995-2010.
17. Bhasin, S., Singh, A. B., Mac, R. P., Carter, B., Lee, M. I., & Cunningham, G. R. (2003). Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. Journal of Andrology, 24, 299-311.
18. Biller, J., & Saver, J. L. (1995). Ischemic cerebrovascular disease and hormone therapy for infertility and transsexualism. Neurology, 45, 1611-1613.
19. Bird, D., Vowles, K., & Anthony, P. P. (1979). Spontaneous rupture of a liver cell adenoma after long term methyltestosterone: Report of a case successfully treated by emergency right hepatic lobectomy. The British Journal of Surgery, 66, 212-213.
20. Blake, W. E., & Pitcher, M. E. (2003). Estrogen-related pancreatitis in the setting of normal plasma lipids: Case report. Menopause, 10, 99-101.
21. Boice Jr., J. D., Friis, S., McLaughlin, J. K., Mellemkjaer, L., Blot, W. J., Fraumeni Jr., J. F., et al. (1997). Cancer following breast reduction surgery in Denmark. Cancer Causes & Control, 8, 253-258. (Pubitemid 27170381)
22. Boice Jr., J. D., Persson, I., Brinton, L. A., Hober, M., McLaughlin, J. K., Blot, W. J., et al. (2000). Breast cancer following breast reduction surgery in Sweden. Plastic and Reconstructive Surgery, 106, 755-762.
23. Bolour, S., & Braunstein, G. (2005). Testosterone therapy inwomen:Areview. International Journal of Impotence Research: Official Journal of the International Society for Impotence Research, 17, 399-408.
24. Bosinski, H. A., Peter, M., Bonatz, G., Arndt, R., Heidenreich, M., Sippell, W. G., et al. (1997). A higher rate of hyperandrogenic disorders in female-to-male transsexuals. Psychoneuroendocrinology, 22, 361-380.
25. Bowman, C., & Goldberg, J. M. (2007). Care of the patient undergoing sex reassignment surgery. International Journal of Transgenderism, 9(3), 135-165.
26. Bradley, S. J., Oliver, G. D., Chernick, A. B., & Zucker, K. J. (1998). Experiment of nurture: Ablatio penis at 2 months, sex reassignment at 7 months, and a psychosexual follow-up in young adulthood. Pediatrics, 102(1), e9. Retrieved September 1, 2009, from http://pediatrics.aappublications.org/ cgi/content/abstract/102/1/e9
27. Brinton, L. A., Persson, I., Boice Jr., J. D., McLaughlin, J. K., & Fraumeni Jr., J. F.. (2001). Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer, 91, 478-483.
28. Bromham, D. (2005). The pharmacological treatment of transsexuals. Retrieved September 1, 2009, from http://tgmeds.org.uk/pharma.html
29. Buffat, J. (2003). Transsexuals: Clinical observations of cross-sex hormone substitution on psychological changes. Sexologies, 12(45), 53-55.
30. Burcombe,R. J., Makris,A., Pittam, M.,&Finer,N. (2003). Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual. Breast, 12, 290-293.
31. Calof, O. M., Singh, A. B., Lee,M. L.,Kenny, A. M.,Urban, R. J., Tenover, J. L., et al. (2005).Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebocontrolled trials. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 60, 1451-1457.
32. Campion, J. M., & Maricic, M. J. (2003). Osteoporosis in men. American Family Physician, 67, 1521-1526.
33. Chasan-Taber, L., Willett, W. C., Stampfer, M. J., Hunter, D. J., Colditz, G. A., Spiegelman, D., et al. (1997). A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care, 20, 330-335.
34. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo Jr., J. L., et al. (2003). Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 42, 1206-1252.
35. Cibula, D., Cifkova, R., Fanta,M., Poledne, R., Zivny, J.,& Skibova, J. (2000). Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Human Reproduction (Oxford, England), 15, 785-789.
36. Cirillo, D. J.,Wallace, R. B., Rodabough, R. J., Greenland, P., LaCroix, A. Z., Limacher,M. C., et al. (2005). Effect of estrogen therapy on gallbladder disease. JAMA: The Journal of the AmericanMedical Association, 293, 330-339.
37. Clements, K., Wilkinson, W., Kitano, K., & Marx, R. (1999). HIV prevention and health service needs of the transgender community in San Francisco. International Journal of Transgenderism, 3(1), 1-17.
38. Colditz, G. A. (2005). Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 11(2), 909s-917s.
39. Coombes, G. B., Reiser, J., Paradinas, F. J., & Burn, I. (1978). An androgen-associated hepatic adenoma in a trans-sexual. The British Journal of Surgery, 65, 869-870.
40. Dahl, M., Feldman, J., Goldberg, J., & Jaberi, A. (2006). Physical aspects of transgender endocrine therapy. International Journal of Transgenderism, 9(3), 111-134.
41. De Laet, C. E., Van Hout, B. A., Burger, H., Hofman, A., & Pols, H. A. (1997). Bone density and risk of hip fracture in men and women: Cross sectional analysis. British Medical Journal (Clinical Research Ed.), 315(7102), 221-225.
42. de Lignìeres, B. (1999). Oral micronized progesterone. Clinical Therapeutics, 21, 41-60.
43. Dean, C. E. (2000). Prasterone (DHEA) and mania. The Annals of Pharmacotherapy, 34, 1419-1422.
44. Dimitrakakis, C., Jones, R. A., Liu, A., & Bondy, C. A. (2004). Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause (New York, N.Y.), 11, 531-535.
45. Dizon, D. S., Tejada-Berges, T., Koelliker, S., Steinhoff, M., & Granai, C. O. (2006). Ovarian cancer associated with testosterone supplementation in a female-to-male transsexual patient. Gynecologic and Obstetric Investigation, 62, 226-228.
46. Dobs, A. S., Meikle, A. W., Arver, S., Sanders, S. W., Caramelli, K. E., & Mazer, N. A. (1999). Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. Journal of Clinical Endocrinology & Metabolism, 84, 3469-3478.
47. Dubey, R. K., Oparil, S., Imthurn, B., & Jackson, E. K. (2002). Sex hormones and hypertension. Cardiovascular Research, 53, 688-708.
48. Ebell, M. H., Siwek, J.,Weiss, B. D.,Woolf, S. H., Susman, J., Ewigman, B., et al. (2004). Strength of recommendation taxonomy (SORT): A patient-centered approach to grading evidence in the medical literature. Journal of the American Board of Family Medicine, 17, 59-67.
49. Egan, R. A.,&Kuyl, J.M. (2002). Ischemic stroke in a man using estrogen. Journal of Stroke and Cerebrovascular Diseases, 11, 117-118.
50. Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999). Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care, 22, 141-146.
51. Elbers, J. M., Asscheman, H., Seidell, J. C., & Gooren, L. J. (1999). Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. The American Journal of Physiology, 276, E317-E325.
52. Elbers, J. M., Asscheman, H., Seidell, J. C., Megens, J. A., & Gooren, L. J. (1997). Long-term testosterone administration increases visceral fat in female to male transsexuals. Journal of Clinical Endocrinology& Metabolism, 82, 2044-2047.
53. Elbers, J.M., Giltay, E. J., Teerlink, T., Scheffer, P. G., Asscheman, H., Seidell, J. C., et al. (2003). Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clinical Endocrinology, 58, 562-571.
54. Erenus,M., Karakoc, B., & Gurler, A. (2001). Comparison of effects of continuous combined transdermal with oral estrogen and oral progestogen replacement therapies on serum lipoproteins and compliance. Climacteric: The Journal of the International Menopause Society, 4, 228-234.
55. Eyler, A. E. (2007). Primary medical care of the gendervariant patient. InR. Ettner, S.Monstrey, E, Eyler (Eds.), Principles of transgendermedicine and surgery (pp. 15-32). Binghamton, NY: Routledge.
56. Eyler, A. E., & Whittle, S. (2001). FTM breast cancer: Community awareness and illustrative cases. 17th Biennial Symposium of the Harry Benjamin International Gender Dysphoria Association, Galveston, TX. Abstract retrieved January 1, 2005, from http://www.symposion.com/ijt/hbigda/2001/41 eyler.htm
57. Factor, R. J., & Rothblum, E. (2008). Exploring gender identity and community among three groups of transgender individuals in the United States: MTFs, FTMs, and gender queers. Health Sociology Review, 17, 235-253.
58. Feldman, J. (2002). New onset of type 2 diabetes mellitus with feminizing hormone therapy: Case series. International Journal of Transgenderism, 6(2). Retrieved January 10, 2008, from http://www.symposion.com/ijt/ijtvo06no02 01.htm
59. Feldman, J. (2005, April). Masculinizing hormone therapy with testosterone 1% topical gel. Paper presented at the 19th Biennial Symposium of the Harry Benjamin International Gender Dysphoria Association, Bologna, Italy.
60. Feldman, J. (2007). Preventive care of the transgendered patient. In R. Ettner, S. Monstrey, & A. E. Eyler (Eds.), Principles of transgender surgery and medicine (pp. 33-72). New York: Haworth Press.
61. Feldman, J., Bockting, W., Allen, S., & Brintell, D. (2003, September). Smoking cessation among transgender persons receiving hormone therapy. Paper presented at the 18th Biennial Symposium of the Harry Benjamin International GenderDysphoria Association, Gent, Belgium.
62. Feldman, J., & Goldberg, J. (2006). Transgender primary medical care. International Journal of Transgenderism, 9(3), 3-34.
63. Fitzpatrick, L. A., Pace,C.,&Wiita,B. (2000).Comparison of regimens containing oral micronized progesterone or medroxyprogesterone acetate on quality of life in postmenopausal women: A cross-sectional survey. Journal of Women's Health & Gender-Based Medicine, 9, 381-387.
64. Flaherty, C., Franicevich, J., Freeman, M., Klein, P., Kohler, L., Lusardi, C., et al. (2001). Protocols for hormonal reassignment of gender. San Francisco: San Francisco Department of Public Health. Retrieved January 1, 2005, from http://www.dph.sf.ca.us /chn/HlthCtrs/HlthCtrDocs/TransGendprotocols.pdf
65. Fortin, C. J., Klein, T.,Messmore, H. L.,&O'Connell, J. B. (1984). Myocardial infarction and severe thromboembolic complications. As seen in an estrogen-dependent transsexual. Archives of Internal Medicine, 144, 1082-1083.
66. Futterweit, W. (1998). Endocrine therapy of transsexualism and potential complications of long-term treatment. Archives of Sexual Behavior, 27, 209-226.
67. Futterweit,W., & Deligdisch, L. (1986). Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. The Journal of Clinical Endocrinology & Metabolism, 62, 16-21.
68. Futterweit, W., & Schwartz, I. (1988). Histopathology of the breasts of 12 women receiving long-term exogenous androgen therapy. TheMount Sinai Journal of Medicine, 55, 309-312.
69. Ganly, I., & Taylor, E. W. (1995). Breast cancer in a transsexual man receiving hormone replacement therapy. British Journal of Surgery, 82(3), 341.
70. Gay and Lesbian Medical Association and LGBT health experts. (2001). Healthy people 2010 companion document for lesbian, gay, bisexual and transgender (LGBT) health. San Francisco, Gay and Lesbian Medical Association. Retrieved September 1, 2009, from http://www.lgbthealth.net/downloads/hp2010doc. pdf
71. Gharib, S., Bigby, J., Chapin, M., Ginsburg, E., Johnson, P., Manson, J., et al. (2005). Menopause: A guide to management. Boston: Brigham and Women's Hospital.
72. Giltay, E. J., & Gooren, L. J. (2000). Effects of sex steroid deprivation/administration on hair growth and skin sebum production in transsexual males and females. Journal of Clinical Endocrinology & Metabolism., 85, 2913-2921.
73. Giltay, E. J., Lambert, J., Gooren, L. J., Elbers, J.M., Steyn, M., & Stehouwer, C. D. (1999). Sex steroids, insulin, and arterial stiffness in women and men. Hypertension, 34, 590-597.
74. Giltay, E. J., Toorians, A. W., Sarabdjitsingh, A. R., De Vries, N. A., & Gooren, L. J. (2004). Established risk factors for coronary heart disease are unrelated to androgen-induced baldness in female-tomale transsexuals. The Journal of Endocrinology, 180, 107-112.
75. Giorgi, A.,Weatherby, R. P.,&Murphy, P.W. (1999).Muscular strength, body composition and health responses to the use of testosterone enanthate: A double blind study. Journal of Science and Medicine in Sport/Sports Medicine Australia, 2, 341-355.
76. Girdler, S. S., Hinderliter, A. L., Wells, E. C., Sherwood, A., Grewen, K. M., & Light, K. C. (2004). Transdermal versus oral estrogen therapy in postmenopausal smokers: Hemodynamic and endothelial effects. American Journal of Obstetrics and Gynecology, 103, 169-180.
77. Godsland, I. F. (2001). Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: Analysis of studies published from 1974-2000. Fertility and Sterility, 75, 898-915.
78. Goh, H. H., Loke, D. F., & Ratnam, S. S. (1995). The impact of long-term testosterone replacement therapy on lipid and lipoprotein profiles in women. Maturitas, 21, 65-70.
79. Goh, H. H., & Ratnam, S. S. (1997). Effects of hormone deficiency, androgen therapy and calcium supplementation on bone mineral density in female transsexuals. Maturitas, 26, 45-52.
80. Goldenberg, N. M., Wang, P., & Glueck, C. J. (2003). An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clinica Chimica Acta: International Journal of Clinical Chemistry, 332, 11-19.
81. Gomes, M. P., & Deitcher, S. R. (2004). Risk of venous thromboembolic disease associatedwith hormonal contraceptives and hormone replacement therapy: A clinical review. Archives of Internal Medicine, 164, 1965-1976.
82. Gooren, L. J. (1999). Hormonal sex reassignment. International Journal of Transgenderism, 3(3) Retrieved January 1, 2005, from http://www.symposion.com/ ijt/ijt990301.htm
83. Gooren, L. J. (2005). Hormone treatment of the adult transsexual patient. Hormone Research, 64 (Suppl.2), 31-36.
84. Gooren, L. J., Assies, J., Asscheman, H., de, Slegte, R., & van Kessel, H. (1988). Estrogen-induced prolactinoma in a man. Journal of Clinical Endocrinology & Metabolism, 66, 444-446.
85. Gooren, L. J., & Bunck, M. C. (2004). Androgen replacement therapy: Present and future. Drugs, 64, 1861-1891.
86. Gooren, L. J., & Giltay, E. J. (2008). Review of studies of androgen treatment of female-to-male transsexuals: Effects and risks of administration of androgens to females. Journal of Sexual Medicine, 5, 765-776.
87. Gooren, L. J., Giltay, E. J., & Bunck, M. C. (2008). Longterm treatment of transsexuals with cross-sex hormones: Extensive personal experience. Journal of Clinical Endocrinology & Metabolism, 93, 19-25.
88. Gordon, E. B. (1991). Transsexual healing-Medicaid funding of sex reassignment surgery. Archives of Sexual Behavior, 20, 61-74.
89. Gorton, R. N., Buth, J., & Spade, D. (2005). Medical therapy and health maintenance for transgender men: A guide for health care providers. San Francisco: Lyon- Martin Women's Health Services.
90. Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., et al. (2002). Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study followup (HERS II). JAMA: The Journal of the American Medical Association, 288, 49-57. (Pubitemid 34705518)
91. Graham, D. G., Spano, M. S., Stewart, T. V., Staton, E.W., Meers, A., & Pace, W. D. (2007). Strategies for planning and launching PBRN research studies: A project of the Academy of Family Physicians National Research Network (AAFP NRN). The Journal of the American Board of Family Medicine, 20, 220-228.
92. Green, L. A., & Hickner, J. (2006). A short history of primary care practice-based research networks: From concept to essential research laboratories. Journal of the American Board of Family Medicine, 19, 1-10.
93. Green, R., & Fleming, D. (1990). Transsexual surgery follow-up: Status in the 1990s. Annual Review of Sex Research, 1, 163-174.
94. Green, R., Newman, L., & Stoller, R. (1972). Treatment of boyhood "transsexualism." Archives of General Psychiatry, 26, 213-217.
95. Greendale, G. A., Edelstein, S., & Barrett-Connor, E. (1997). Endogenous sex steroids and bone mineral density in older women and men: The Rancho Bernardo study. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 12, 1833-1843. (Pubitemid 27500195)
96. Grodstein, F., Colditz, G. A., & Stampfer, M. J. (1994). Postmenopausal hormone use and cholecystectomy in a large prospective study. American Journal of Obstetrics and Gynecology, 83, 5-11.
97. Grodstein, F., Manson, J. E.,&Stampfer,M. J. (2001). Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. A prospective, observational study. Annals of Internal Medicine, 135, 1-8.
98. Hachulla, E., Rose, C., Trillot, N., Caulier-Leleu, M. T., & Pasturel-Michon, U. (2000). What vascular events suggest a myeloproliferative disorder? Journal des Maladies Vasculaires, 25, 382-387.
99. Hage, J. J., Dekker, J. J., Karim, R. B., Verheijen, R. H., & Bloemena, E. (2000). Ovarian cancer in female-tomale transsexuals: Report of two cases. Gynecologic Oncology, 76, 413-415.
100. Hajjar, R. R., Kaiser, F. E., & Morley, J. E. (1997). Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. Journal of Clinical Endocrinology Metabolism, 82, 3793-3796.
101. Hak, A. E., Witteman, J. C. M., de Jong, F. H., Geerlings, M. I.,Hofman, A.,&Pols,H.A. P. (2002). Lowlevels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. Journal of Clinical Endocrinology & Metabolism, 87, 3632-3639.
102. Hall, R. C.,&Hall, R. C. (2005).Abuse of supraphysiologic doses of anabolic steroids. Southern Medical Journal, 98(5), 550-555.
103. Hannan Jr., C. J., Friedl, K. E., Zold, A., Kettler, T. M., & Plymate, S. R. (1991). Psychological and serum homovanillic acid changes in men administered androgenic steroids. Psychoneuroendocrinology, 16, 335-343.
104. Haraldsen, I. R., Haug, E., Falch, J., Egeland, T., & Opjordsmoen, S. (2007). Cross-sex pattern of bone mineral density in early onset gender identity disorder. Hormones and Behavior, 52, 334-343.
105. Hardiman, P., Pillay, O. C., & Atiomo,W. (2003). Polycystic ovary syndrome and endometrial carcinoma. Lancet, 361(9371), 1810-1812. (Pubitemid 36638434)
106. Heino, F., & Meyer-Bahlburg, H. (2005). Gender identity outcome in female-raised 46, XY persons with penile agenesis, cloacal exstrophy of the bladder, or penile ablation. Archives of Sexual Behavior, 34, 423-438.
107. Hembree, W. C., Cohen-Kettenis, P., Delemarre-Van De Waal, H. A., Gooren, L. J., Meyer III, W. J., Spack, N. P., et al. (2009). Endocrine treatment of transsexual persons: An endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 94, 3132-3154.
108. Hemelaar, M., Van Der Mooren, M. J., Mijatovic, V., Bouman, A. A., Schijf, C., Kroeks, M. V. A. M., et al. (2003). Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein (a) in postmenopausal women: A randomized, placebo-controlled study. Menopause, 10, 550-558.
109. Holte, J., Gennarelli, G., Wide, L., Lithell, H., & Berne, C. (1998). High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 83, 1143-1150.
110. Inoue, H., Nishida, N., Ikeda, N., Tsuji, A., Kudo, K., Hanagama, M., et al. (2007). The sudden and unexpected death of a female-to-male transsexual patient. Journal of Forensic and Legal Medicine, 14, 382-386.
111. Jacobeit, J. W., Gooren, L. J., & Schulte, H. M. (2007). Long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals. Journal of Sexual Medicine, 4, 1479-1484.
112. Jick, H. (2000). Incidence of venous thromboembolism in users of combined oral contraceptives. Methods for identifying cases and estimating person time at risk must be detailed. British Medical Journal (Clinical Research Ed.), 320(7226), 57-58.
113. Jockenḧovel, F. (2004). Testosterone therapy-what, when and to whom? The Aging Male, 7, 319-324.
114. Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006). Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology/ European Federation of Endocrine Societies, 154, 899-906.
115. Kirk, S. (1999). Feminizing hormonal therapy for the transgendered. Pittsburgh, PA: Together Lifeworks.
116. Koh-Banerjee, P., Wang, Y., Hu, F. B., Spiegelman, D., Willett,W. C., & Rimm, E. B. (2004). Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men. American Journal of Epidemiology, 159, 1150-1159.
117. Kovacs, K., Stefaneanu, L., Ezzat, S., & Smyth, H. S. (1994). Prolactin-producing pituitary adenoma in a male-to-female transsexual patient with protracted estrogen administration. A morphologic study. Archives of Pathology & Laboratory Medicine, 118, 562-565.
118. Kruijver, F. P. M., Zhou, J. N., Pool, C. W., Hofman, M. A., Gooren, L. J. G., & Swaab, D. F. (2000). Male-tofemale transsexuals have female neuron numbers in a limbic nucleus. Journal of Clinical Endocrinology & Metabolism, 85, 2034-2041.
119. Kwan,M., VanMaasdam, J.,&Davidson, J. M. (1985). Effects of estrogen treatment on sexual behavior in maleto- female transsexuals: Experimental and clinical observations. Archives of Sexual Behavior, 14, 29-40.
120. Lane, D. A., Shah, S., & Beevers, D. G. (2007). Low-dose spironolactone in the management of resistant hypertension: A surveillance study. Journal of Hypertension, 25, 891-894.
121. Lawrence, A. A., Shaffer, J. D., Snow, W. R., Chase, C., & Headlam, B. T. (1996). Health care needs of transgendered patients [Letter to the editor]. JAMA: The Journal of the American Medical Association, 276, 874.
122. Legro, R. S. (2003). Polycystic ovary syndrome and cardiovascular disease: A premature association? Endocrine Reviews, 24, 302-312.
123. Levy, A., Crown, A., & Reid, R. (2003). Endocrine intervention for transsexuals. Clinical Endocrinology, 59, 409-418.
124. Liao, D. J., & Dickson, R. B. (2002). Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. The Journal of Steroid Biochemistry and Molecular Biology, 80, 175-189.
125. Liu, P. Y., Death, A. K., & Handelsman, D. J. (2003). Androgens and cardiovascular disease. Endocrine Reviews, 24, 313-340.
126. Lombardi, E. (2001). Enhancing transgender health care. American Journal of Public Health, 91, 869-872.
127. Loverro, G. (2004). Polycystic ovary syndrome and cardiovascular disease. Minerva Endocrinologica, 29, 129-138.
128. Lubbert, H., Leo-Rossberg, I., & Hammerstein, J. (1992). Effects of ethinyl estradiol on semen quality and various hormonal parameters in a eugonadal male. Fertility and Sterility, 58, 603-608.
129. MacIndoe, J. H. (2003). The challenges of testosterone deficiency. Uncovering the problem, evaluating the role of therapy. Postgraduate Medicine, 114(4), 51-58, 61.
130. Manjer, J., Johansson, R., Berglund, G., Janzon, L., Kaaks, R., Agren, A., et al. (2003). Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes & Control: CCC, 14, 599-607.
131. Manson, J. E., Rimm, E. B., Colditz, G. A., Willett, W. C., Nathan, D. M., Arky, R. A., et al. (1992). A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Annals of Epidemiology, 2, 665-673.
132. Markland, C. (1975). Transexual surgery. Obstetrics and Gynecology Annual, 4, 309-330.
133. Markowitz, J. S., Carson, W. H., & Jackson, C. W. (1999). Possible dihydroepiandrosterone-induced mania. Biological Psychiatry, 45, 241-242.
134. Marrazzo, J. M., Koutsky, L. A., Stine, K. L., Kuypers, J. M., Grubert, T. A., Galloway, D. A., et al. (1998). Genital human papillomavirus infection in women who have sex with women. The Journal of Infectious Diseases, 178, 1604-1609.
135. McCredie, R. J., McCrohon, J. A., Turner, L., Griffiths, K. A., Handelsman, D. J., & Celermajer, D. S. (1998). Vascular reactivity is impaired in genetic females taking high-dose androgens. Journal of the American College of Cardiology, 32, 1331-1335.
136. McPherson, K., Steel, C. M., & Dixon, J. M. (2000). ABC of breast diseases, breast cancer-epidemiology, risk factors, and genetics. British Medical Journal (Clinical Research Ed.), 321(7261), 624-628.
137. Melnikow, J., Nuovo, J., Willan, A. R., Chan, B. K., & Howell, L. P. (1998). Natural history of cervical squamous intraepithelial lesions:Ameta-analysis. American Journal of Obstetrics and Gynecology, 92, 727-735.
138. Meyer III, W. J., Bockting, W. O., Cohen-Kettenis, P., Coleman, E., Di Ceglie, D., Devor, H., et al. (2001). The Standards of Care for Gender Identity Disorders. Minneapolis, MN: Harry Benjamin International Gender Dysphoria Association.
139. Meyer III, W. J., Walker, P. A., & Suplee, Z. R. (1981). A survey of transsexual hormonal treatment in twenty gender-treatment centers. Journal of Sex Research, 17, 344-349.
140. Meyer III, W. J., Webb, A., Stuart, C. A., Finkelstein, J. W., Lawrence, B., & Walker, P. A. (1986). Physical and hormonal evaluation of transsexual patients: A longitudinal study. Archives of Sexual Behavior, 15, 121-138.
141. Meyer-Bahlburg, H., Migeon, C., Berkovitz, G., Gearhart, J., Dolezal, C., & Wisniewski, A. (2004). Attitudes of adult 46, XY intersex persons to clinical management policies. The Journal of Urology, 171, 1615-1619.
142. Miller, N., Bedard, Y. C., Cooter, N. B., & Shaul, D. L. (1986). Histological changes in the genital tract in transsexual women following androgen therapy. Histopathology, 10, 661-669.
143. Missmer, S. A., Eliassen, A. H., Barbieri, R. L., & Hankinson, S. E. (2004). Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausalwomen. Journal of the National Cancer Institute, 96, 1856-1865.
144. Money, J. (1994). Sex errors of the body and related syndromes: A guide to counseling children, adolescents, and their families. Baltimore, MD: Paul H. Brookes Publishing.
145. Monstrey, S., Ceulemans, P.,&Hoebke, P. (2007). Surgery: Female-to-male patient. In R. Ettner, S. Monstrey & A. E. Eyler (Eds.), Principles of transgender medicine and surgery (pp. 135). New York: Routledge.
146. Moore, E., Wisniewski, A., & Dobs, A. (2003). Endocrine treatment of transsexual people: A review of treatment regimens, outcomes, and adverse effects. The Journal of Clinical Endocrinology & Metabolism, 88, 3467-3473.
147. Mueller, A., Kiesewetter, F., Binder, H., Beckmann, M. W., & Dittrich, R. (2007). Long-term administration of testosterone undecanoate every 3 months for testosterone supplementation in female-to-male transsexuals. The Journal of Clinical Endocrinology & Metabolism, 92, 3470-3475.
148. Mullins, G., O'Sullivan, S., Kinsella, J., McEnroy, D., Crimmins, D., Whyte, S., et al. (2008). Venous and arterial thrombo-embolic complications of hormonal treatment in a male-to-female transgender patient. Journal of Clinical Neuroscience, 15, 714-716.
149. Nelson, H. D., Humphrey, L. L., Nygren, P., Teutsch, S. M., & Allan, J. D. (2002). Postmenopausal hormone replacement therapy: Scientific review. JAMA: The Journal of the American Medical Association, 288, 872-881.
150. Netscher, D., Meade, R. A., Friedman, J. D.,Malone, R. S., Brady, J. R., & Thornby, J. (1999). Mammography and reduction mammaplasty. Aesthetic Surgery Journal, 19, 445-451.
151. New, G., Berry, K. L., Cameron, J. D., Harper, R. W., & Meredith, I. T. (2000). Long-term oestrogen treatment does not alter systemic arterial compliance and haemodynamics in biological males. Coronary ArteryDisease, 11, 253-259.
152. New,G., Timmins, K. L.,Duffy, S. J., Tran,B. T., O'Brien, R. C., Harper, R. W., et al. (1997). Long-term estrogen therapy improves vascular function in male to female transsexuals. Journal of the American College of Cardiology, 29, 1437-1444.
153. Nieschlag, E., & Behre, H. (1998). Pharmacology and clinical uses of testosterone. In E. Nieschlag & H. Behre (Eds.), Testosterone: Action, deficiency, substitution (pp. 293-328). Berlin, Germany: Springer.
154. Nieschlag, E., Behre, H., Bouchard, P., Corrales, J., Jones, T., Stalla, G., et al. (2004). Testosterone replacement therapy: Current trends and future directions. Human Reproduction Update, 10, 409-419.
155. Norman, R. J.,Masters, L., Milner, C. R.,Wang, J. X., & Davies, M. J. (2001). Relative risk of conversion from normoglycaemia to impaired glucose tolerance or noninsulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reproduction (Oxford, England), 16, 1995-1998.
156. Oh, J. Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002). Endogenous sex hormones and the development of type 2 diabetes in older men and women: TheRanchoBernardo study. DiabetesCare, 25, 55-60.
157. Oriel, K. A. (2000). Medical care of transsexual patients. Journal of the Gay and LesbianMedical Association, 4, 185-194.
158. Ouzan, J., Catherine, P., Lincoff, A. M., Carr, E., & Mertes, M. (2002). The role of spironolactone in the treatment of patientswith refractory hypertension. American Journal of Hypertension, 15, 333-339.
159. Pache, T. D., Chadha, S., Gooren, L. J., Hop, W. C., Jaarsma, K.W., Dommerholt, H. B., et al. (1991). Ovarian morphology in long-term androgen-treated female to male transsexuals. A human model for the study of polycystic ovarian syndrome? Histopathology, 19, 445-452.
160. Paradinas, F. J., Bull, T. B., Westaby, D., & Murray-Lyon, I. M. (1977). Hyperplasia and prolapse of hepatocytes into hepatic veins during long term methyltestosterone therapy: Possible relationships of these changes to the developement of peliosis hepatis and liver tumours. Histopathology, 1, 225-246.
161. Parish, S. J., & Clayton, A. H. (2007). Sexual medicine education: Review and commentary (CME). Journal of Sexual Medicine, 4, 259-268.
162. Parssinen, M., & Seppala, T. (2002). Steroid use and longterm health risks in former athletes. Sports Medicine (Auckland, N.Z.), 32, 83-94.
163. Pauly, I. B. (1974). Female transsexualism: Part II. Archives of Sexual Behavior, 3, 509-526.
164. Perego, E., Scaini, A., Romano, F., Franciosi, C.,&Uggeri, F. (2004). Estrogen-induced severe acute pancreatitis in a male. Journal of the Pancreas, 5, 353-356.
165. Peverill, R. E. (2003). Hormone therapy and venous thromboembolism. Bailliere's Best Practice & Research. Clinical Endocrinology & Metabolism, 17, 149-164.
166. Pfafflin, F., & Junge, A. (1998). Sex reassignment: Thirty years of international follow-up studies SRS-A comprehensive review, 1961-1991. D̈usseldorf, Germany: Symposion.
167. Phornphutkul, C., Fausto-Sterling, A., & Gruppuso, P. A. (2000). Gender self-reassignment in an XY adolescent female born with ambiguous genitalia. Pediatrics, 106, 135-137.
168. Physicians' desk reference (61st ed.). (2007). Montavale, NJ: Thomson PDR.
169. Pierpoint, T., McKeigue, P. M., Isaacs, A. J., Wild, S. H., & Jacobs, H. S. (1998). Mortality of women with polycystic ovary syndrome at long-term follow-up. Journal of Clinical Epidemiology, 51, 581-586.
170. Pope Jr., H. G.,Kouri, E. M.,&Hudson, J. I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial. Archives of General Psychiatry, 57, 133-140.
171. Prior, J. C., Vigna, Y.M.,&Watson, D. (1989). Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Archives of Sexual Behavior, 18, 49-57.
172. Prior, J. C., Vigna, Y.M.,Watson, D., Diewold, P., & Robinow, O. (1986). Spironolactone in the presurgical therapy of male to female transsexuals: Philosophy and experience of the Vancouver Gender Dysphoria Clinic. Journal of Sex Information and Education Council of Canada, 1, 1-7.
173. Pritchard, T. J., Pankowsky, D. A., Crowe, J. P., & Abdul-Karim, F. W. (1988). Breast cancer in a male-to-female transsexual. A case report. JAMA: The Journal of the American Medical Association, 259, 2278-2280.
174. Pryor, J. (2006). The European Academy for Sexual Medicine (EASM): The challenge of developing European training standards in sexual medicine. Sexual and Relationship Therapy, 21, 273-279.
175. Quigley, C., De Bellis, A., Marschke, K., El-Awady, M., Wilson, E., & French, F. (1995). Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocrine Reviews, 16, 271-321.
176. Reiner, W. G., & Gearhart, J. P. (2004). Discordant sexual identity in some genetic males with cloacal exstrophy assigned to female sex at birth. New England Journal of Medicine, 350, 333-341.
177. Resnick, H. E., Valsania, P., Halter, J. B., & Lin, X. (2000). Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. Journal of Epidemiology & Community Health, 54, 596-602.
178. Rhoden, E. L., & Morgentaler, A. (2004). Risks of testosterone-replacement therapy and recommendations for monitoring. The New England Journal of Medicine, 350, 482-492.
179. Riggs, B. L., Khosla, S., & Melton III, L. J. (1998). A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 13, 763-773.
180. Rimm, E. B.,Manson, J. E., Stampfer,M. J., Colditz, G. A., Willett,W. C., Rosner, B., et al. (1992). Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women. Diabetologia, 35, 967-972.
181. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women's health initiative randomized controlled trial. JAMA: The Journal of the American Medical Association, 288, 321-333.
182. Russell-Briefel, R., Ezzati, T. M., Perlman, J. A., & Murphy, R. S. (1987). Impaired glucose tolerance in women using oral contraceptives: United States, 1976-1980. Journal of Chronic Diseases, 40, 3-11.
183. Sader, M. A., Griffiths, K. A., Skilton, M. R., Wishart, S. M., Handelsman, D. J., & Celermajer, D. S. (2003). Physiological testosterone replacement and arterial endothelial function in men. Clinical Endocrinology, 59, 62-67.
184. Sanada, M., Tsuda, M., Kodama, I., Sakashita, T., Nakagawa, H., & Ohama, K. (2004). Substitution of transdermal estradiol during oral estrogen-progestin therapy in postmenopausal women: Effects on hypertriglyceridemia. Menopause, 11, 331-336.
185. Sarlis, N. J.,Weil, S. J., & Nelson, L. M. (1999). Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin:Management of infertility and prevention of inadvertent masculinization of a female fetus. The Journal of Clinical Endocrinology & Metabolism, 84, 1510-1512.
186. Scarabin, P. Y., Oger, E., & Plu-Bureau, G. (2003). Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet, 362(9382), 428-432.
187. Schairer, C., Lubin, J., Troisi, R., Sturgeon, S., Brinton, L., & Hoover, R. (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA: The Journal of the American Medical Association, 283, 485-491. (Pubitemid 30062864)
188. Schildkraut, J. M., Schwingl, P. J., Bastos, E., Evanoff, A., & Hughes, C. (1996). Epithelial ovarian cancer risk among women with polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 88, 554-559.
189. Schlatterer, K., Von Werder, K., & Stalla, G. K. (1996). Multistep treatment concept of transsexual patients. Experimental & Clinical Endocrinology & Diabetes, 104, 413-419.
190. Schlatterer, K., Yassouridis, A., Von Werder, K., Poland, D., Kemper, J., & Stalla, G. K. (1998). A follow-up study for estimating the effectiveness of a cross-gender hormone substitution therapy on transsexual patients. Archives of Sexual Behavior, 27, 475-492.
191. Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2005). Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Archives of Pediatrics & Adolescent Medicine, 159, 139-144.
192. Schulze, C. (1988). Response of the human testis to longterm estrogen treatment: Morphology of sertoli cells, leydig cells and spermatogonial stem cells. Cell and Tissue Research, 251, 31-43.
193. Serri, O., Noiseux, D., Robert, F., & Hardy, J. (1996). Lactotroph hyperplasia in an estrogen treated maleto- female transsexual patient. Journal of Clinical Endocrinology and Metabolism, 81, 3177-3179.
194. Sherman, M. E., Lorincz, A. T., Scott, D. R., Wacholder, S., Castle, P. E., Glass, A. G., et al. (2003). Baseline cytology, human papilloma virus testing, and risk for cervical neoplasia: A 10-year cohort analysis. Journal of the National Cancer Institute, 95, 46-52.
195. Shortell, C. K., & Schwartz, S. I. (1991). Hepatic adenoma and focal nodular hyperplasia. Surgery, Gynecology & Obstetrics, 173, 426-431.
196. Slabbekoorn, D., Van Goozen, S., Gooren, L., & Cohen-Kettenis, P. (2001). Effects of cross-sex hormone treatment on emotionality in transsexuals. International Journal of Transgenderism, 5(3). Retrieved January 10, 2009, from http://www.symposion.com /ijt/ijtvo05no03 02htm)
197. Smith, Y. L. S., Van Goozen, S. H. M., Kuiper, A. J., & Cohen-Kettenis, P. T. (2005). Sex reassignment: Outcomes and predictors of treatment for adolescent and adult transsexuals. Psychological Medicine, 35, 89-99.
198. Somboonporn, W., & Davis, S. R. (2004). Testosterone effects on the breast: Implications for testosterone therapy for women. Endocrine Reviews, 25, 374-388.
199. Spinder, T., Spijkstra, J. J., van den Tweel, J. G., Burger, C. W., van Kessel H., Hompes, P. G., et al. (1989). The effects of long term testosterone administration on pulsatile luteinizing hormone secretion and on ovarian histology in eugonadal female tomale transsexual subjects. The Journal of Clinical Endocrinology & Metabolism, 69, 151-157.
200. Spritz, M. (2003, September). Effects of cross gender hormonal therapy on prostates of 20 male-to-female postoperative patients. Paper presented at the 18th Biennial Symposium of the Harry Benjamin International Gender Dysphoria Association, Gent, Belgium.
201. Steinbeck, A. (1997). Hormonal medication for transsexuals. Venereology, 10, 175-177.
202. Su, T. P., Pagliaro,M., Schmidt, P. J., Pickar,D.,Wolkowitz, O., & Rubinow, D. R. (1993). Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA: The Journal of the American Medical Association, 269, 2760-2764.
203. Symmers, W. S. (1968). Carcinoma of breast in transsexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. British Medical Journal, 2(597), 82-85.
204. Tan, R. S.,&Culberson, J.W. (2003).An integrative review on current evidence of testosterone replacement therapy for the andropause. Maturitas, 45, 15-27.
205. Tangpricha, V., Ducharme, S. H., Barber, T. W., & Chipkin, S. R. (2003). Endocrinologic treatment of gender identity disorders. Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 9, 12-21.
206. Tangpricha, V., Turner, A., Malabanan, A., & Holick, M. (2001). Effects of testosterone therapy on bone mineral density in the FTM patient. International Journal of Transgenderism, 5(4). Retrieved January 10, 2008, from http://symposion.com/ijt/hbigda/2001/39 tangpricha.htm
207. Tangredi, J. F., & Buxton, I. L. (2001). Hypertension as a complication of topical testosterone therapy. The Annals of Pharmacotherapy, 35, 1205-1207.
208. Teede, H. J., Liang, Y. L., Kotsopoulos, D., Zoungas, S., Craven, R., & McGrath, B. P. (2002). Placebocontrolled trial of transdermal estrogen therapy alone in postmenopausal women: Effects on arterial compliance and endothelial function. Climacteric: The Journal of the International Menopause Society, 5, 160-169.
209. Thaler, C. (2007). Putting transgender health care myths on trial. Retrieved September 1, 2009, from http://www. lambdalegal.org/our-work/ publications/page-32007335.html
210. Third Expert Panel on the Management of Asthma. (2007). Expert panel report 3: Guidelines for the diagnosis and management of asthma (NIH Publication Number 08- 5846). Bethesda, MD: National Heart, Lung, and Blood Institute.
211. Thole, Z., Manso, G., Salgueiro, E., Revuelta, P., & Hidalgo, A. (2004). Hepatotoxicity induced by antiandrogens: A review of the literature. Urologia Internationalis, 73, 289-295.
212. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia,M. S., Parnes, H. L., et al. (2004). Prevalence of prostate cancer among men with a prostate-specific antigen level
213. Toorians, A. W., Gooren, L. J., & Asscheman, H. (2001). Venous thromboembolism and (oral) estrogen use [Abstract]. International Journal of Transgenderism, 5 (4). Retrieved January 10, 2008, from http://www.symposion. com/ijt/hbigda/2001/43 toorians.htm
214. Toorians,A.W., Thomassen, M. C., Zweegman, S.,Magdeleyns, E. J., Tans, G., Gooren, L. J., et al. (2003). Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. The Journal of Clinical Endocrinology and Metabolism, 88, 5723-5729.
215. Turner, A., Chen, T. C., Barber, T. W., Malabanan, A. O., Holick, M. F., & Tangpricha, V. (2004). Testosterone increases bone mineral density in female-to-male transsexuals: A case series of 15 subjects. Clinical Endocrinology, 61, 560-566.
216. Vacheron-Trystram,M.N., Cheref, S., Gauillard, J.,&Plas, J. (2002). A case report of mania precipitated by use of DHEA. L'Encephale, 28, 563-566.
217. Van Haarst, E. P., Newling, D. W., Gooren, L. J., Asscheman, H., & Prenger, D. M. (1998). Metastatic prostatic carcinoma in amale-to-female transsexual. British Journal of Urology, 81, 776.
218. Van Kesteren, P. J., Asscheman, H., Megens, J. A., & Gooren, L. J. (1997). Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology, 47, 337-342.
219. Van Kesteren, P. J., Gooren, L. J., & Megens, J. A. (1996). An epidemiological and demographic study of transsexuals in The Netherlands. Archives of Sexual Behavior, 25, 589-600.
220. Van Kesteren, P. J., Lips, P., Gooren, L. J., Asscheman, H., &Megens, J. (1998). Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones. Clinical Endocrinology, 48, 347-354.
221. Viallard, J., Marit, G., Mercie, P., Leng, B., Reiffers, J., & Pellegrin, J. (2000). Polycythaemia as a complication of transdermal testosterone therapy [Letter to the editor]. British Journal of Haematology, 110, 237-238.
222. Vongpatanasin, W., Tuncel, M., Wang, Z., Arbique, D., Mehrad, B., & Jialal, I. (2003). Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. Journal of the American College of Cardiology, 41, 1358-1363.
223. Wagner, G. (2005). Sexual medicine in the medical curriculum. International Journal of Andrology, 28, 7-8.
224. Wald,M., Meacham, R. B., Ross, L. S., & Niederberger, C. S. (2006). Testosterone replacement therapy for older men. Journal of Andrology, 27, 126-132.
225. Wang, C., Swerdloff, R., Iranmanesh, A., & Dobs, A. (2000). Testosterone gel study group, et al. transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Inpharma, 1(1254), 14-14
226. Watanabe, S.,Yamasaki, S., Tanae, A.,Hibi, I.,&Honna, T. (1994). Three cases of hepatocellular carcinoma among cyproterone users. Ad hoc committee on androcur users. Lancet, 344(8936), 1567-1568.
227. Weiss, E. L., Bowers Jr., M. B., & Mazure, C. M. (1999). Testosterone-patch-induced psychotic mania [Letter to the editor]. The American Journal of Psychiatry, 156, 969-969
228. Whitsel, E. A., Boyko, E. J., Matsumoto, A. M., Anawalt, B. D., & Siscovick, D. S. (2001). Intramuscular testosterone esters and plasma lipids in hypogonadal men: A meta-analysis. The American Journal of Medicine, 111, 261-269.
229. Wild, S., Pierpoint, T., Jacobs, H., & McKeigue, P. (2000). Long-term consequences of polycystic ovary syndrome: Results of a 31 year follow-up study. Human Fertility, 3, 101-105.
230. World Health Organization. (2008). The World Health Report 2008: Primary health care-now more than ever. Geneva, Switzerland: World Health Organization.
231. Xavier, J. (2000). The Washington, D.C. transgender needs assessment survey: Final report for phase two. Washington, DC: Administration for HIV/AIDS of District of Columbia Government.
232. Zitzmann, M., Saad, F., & Nieschlag, E. (2006). Long term experience of more than 8 years with a novel formulation of testosterone undecanoate (nebido) in substitution therapy of hypogonadal men [Abstract]. Paper presented at European Congress of Endocrinology, Glasgow, UK, April 2006. Endocrine Abstracts, 11, P178.